John W. Feik

John Feik saw the untapped potential in a pharmaceutical manufacturing company, acquiring it in 1990 to form the foundation of DFB Pharmaceuticals. Over the next 22 years, he led DFB and its subsidiaries to more than $400 million in annual sales.

Feik guided the growth of DFB’s DPT Laboratories unit, which provides the pharmaceutical and biotech industry with drug development, manufacturing and packaging solutions. DPT clients include the world’s leading pharmaceutical, biotech and specialty pharmaceutical companies.

In addition he oversaw DFB’s Healthpoint Biotherapeutics, which was later acquired by Smith & Nephew, and other DFB operating units. Mr. Feik holds numerous civic leadership posts, including board positions at the Texas Research & Technology Foundation and the Texas Biomedical Research Institute.

He and Mrs. Feik founded the John & Rita Feik School of Pharmacy at the University of the Incarnate Word and underwrote the Rita & John Feik Distinguished Chair for Medicinal Chemistry at the University of Texas at San Antonio.

Mr. Feik holds a bachelor’s in finance from the University of Texas at Arlington.